No products in the cart.
In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall Street giving Biogen another chance.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
![[GOOD PRESS] ON](https://georgemagazine.com/wp-content/uploads/2023/07/95743-300x300.jpg)
